ABBOTT LABORATORIES
For the period ended Dec 31, 2023. Filed Feb 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 16, 2024
ABT$109.93-3.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Cash Flows
| Year Ended December 31 | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $5,723 | $6,933 | $7,071 |
| Adjustments to reconcile earnings to net cash from operating activities — | |||
| Depreciation | 1,277 | 1,254 | 1,491 |
| Amortization of intangible assets | 1,966 | 2,013 | 2,047 |
| Share-based compensation | 644 | 685 | 640 |
| Investing and financing losses, net | 126 | 215 | 55 |
| Trade receivables | (356) | (68) | (383) |
| Inventories | (232) | (1,413) | (456) |
| Prepaid expenses and other assets | (542) | (75) | (312) |
| Trade accounts payable and other liabilities | (760) | 420 | 1,288 |
| Income taxes | (585) | (383) | (908) |
| Net Cash From Operating Activities | 7,261 | 9,581 | 10,533 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (2,202) | (1,777) | (1,885) |
| Acquisitions of businesses and technologies, net of cash acquired | (877) | — | (187) |
| Proceeds from business dispositions | 40 | 48 | 134 |
| Purchases of investment securities | (159) | (185) | (173) |
| Proceeds from sales of investment securities | 43 | 152 | 77 |
| Other | 22 | 22 | 26 |
| Net Cash From (Used in) Investing Activities | (3,133) | (1,740) | (2,008) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | 21 | 47 | (204) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 2 | 7 | 4 |
| Repayments of long-term debt and debt with maturities over 3 months | (2,498) | (753) | (48) |
| Purchases of common shares | (1,227) | (3,795) | (2,299) |
| Proceeds from stock options exercised | 167 | 167 | 255 |
| Dividends paid | (3,556) | (3,309) | (3,202) |
| Net Cash From (Used in) Financing Activities | (7,091) | (7,636) | (5,494) |
| Effect of exchange rate changes on cash and cash equivalents | (23) | (122) | (70) |
| Net Increase (Decrease) in Cash and Cash Equivalents | (2,986) | 83 | 2,961 |
| Cash and Cash Equivalents, Beginning of Year | 9,882 | 9,799 | 6,838 |
| Cash and Cash Equivalents, End of Year | $6,896 | $9,882 | $9,799 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | $1,475 | $1,864 | $1,941 |
| Interest paid | 662 | 563 | 544 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.